Single-dose dalbavancin has shown positive outcomes for the treating serious skin infections and can be a significant new treatment option for patients, said David Nicholson, Actavis Executive Vice President, Global Brands R&D. Furthermore, the trial assessed the secondary result measures of medical response at Day 14 along with at Day 28. The single-dosage of DALVANCE provided equivalent treatment efficacy to both dose routine in these secondary endpoints. 94.4 percent of individuals in the single-dosage DALVANCE arm and 94.0 percent of patients in the two-dosage DALVANCE arm achieved medical success at Day 14 .Another 26 % were free from seizures at either 2 yrs after medical procedures or five years after surgery treatment, but not both. The remaining 18 % still experienced seizures at both two and five years following the surgery. The quality of life scores remained stable for individuals who still experienced seizures but didn’t have any memory complications. Standard of living scores declined limited to those that had both memory and seizures problems, which was eight % of the individuals. Because certain risk factors make people much more likely to possess memory complications after surgery and additional risk elements make people more likely to continue to possess seizures after procedure, doctors may use these leads to help determine who is an excellent candidate for medical procedures and also to closely monitor those people who are at risk, Langfitt stated.